Penn Capital Management Company LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

Penn Capital Management Company LLC purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 153,877 shares of the medical equipment provider’s stock, valued at approximately $17,089,000. Penn Capital Management Company LLC owned approximately 0.24% of Lantheus as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. ABS Investment Management LLC bought a new stake in shares of Lantheus during the second quarter valued at about $232,974,000. Western Wealth Management LLC purchased a new position in Lantheus during the first quarter valued at approximately $25,000. Osterweis Capital Management Inc. bought a new stake in Lantheus during the 2nd quarter worth approximately $36,000. Allworth Financial LP purchased a new stake in Lantheus in the 2nd quarter worth approximately $49,000. Finally, Smartleaf Asset Management LLC boosted its holdings in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $100.77 on Friday. The company has a market capitalization of $6.58 billion, a price-to-earnings ratio of 24.34 and a beta of -0.03. The business has a 50 day moving average of $103.74 and a 200 day moving average of $91.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. Lantheus Holdings, Inc. has a 1-year low of $49.67 and a 1-year high of $111.86.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the firm posted $1.57 earnings per share. The business’s revenue was up 2.7% compared to the same quarter last year. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on LNTH shares. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and dropped their price objective for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. Weiss Ratings raised Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Finally, William Blair set a $102.50 price target on shares of Lantheus in a report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.